Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Showing posts with label PCCA. Show all posts
Showing posts with label PCCA. Show all posts
Saturday, February 8, 2014
Saturday, September 7, 2013
Fifth Question of the Day September 7, 2013 How will Imprimis Pharmaceuticals, Inc. with its exclusive relationship with PCCA to commercialize compounded drug formulations utilizing the FDA 505(b)(2) drug develop and predicted to become a large pharmaceutical company in a relatively short period of time impact compounding pharmacies?
For more information on Imprimis --
News
By M.E. Garza: Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) has seen its stock rise from about $5.25 per share in February at the time of the NASDAQ listing to around $9 per share and is one of the...
Imprimis Pharmaceuticals, focused on the commercialization of drug formulations through a growing proprietary network of compounding pharmacy relationships, has acquired intellectual property from Nov...
Imprimis Pharmaceuticals, Inc., which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) development pathway, today announced it has received IRB approval...
SAN DIEGO, Aug. 5, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) drug develop...
Imprimis Pharmaceuticals has received approval from the Institutional Review Board (IRB) to initiate Phase III clinical trial protocol of its new topical non-steroidal anti-inflammatory drug (NSAID) c...
Imprimis Pharmaceuticals has acquired the intellectual property (IP) rights related to proprietary innovations from the compounding pharmacy operations of Ohio-based Buderer Drug, a compounding pharma...
By MarketScanners:Wall Street is littered with failed companies that had great business plans, but did not have management capable of fulfilling the plan's promise. Good investors know management team...
USA-based Imprimis Pharmaceuticals (Nasdaq: IMMY), which is focused on the commercialization of drug formulations through a growing proprietary network of compounding pharmacy relationships and by uti...
Wednesday, July 3, 2013
PCCA Compounding Courses
Class Schedule
Read course descriptions here.
Introductory Compounding Lab Boot Camp
- Status: Sold out
- Location: Houston, Texas
- Date: August 12-13, 2013
- Status: Click to register
- Location: Houston, Texas
- Date: December 12-13, 2013
Advanced Compounding Training Program - Fall 2013 (10-Week Online Component and Lab)
- Status: Click to register
- Location: Houston, TX
- Date: September 9, 2013
Veterinary Compounding Training Program - Fall 2013 (10-Week Online Component and Lab)
- Status: Click to register
- Location: Houston, TX
- Date: September 9, 2013
Veterinary Compounding Training Program - Fall 2013 (10-Week Online Component ONLY)
- Status: Click to register
- Location: Houston, TX
- Date: September 9, 2013
Subscribe to:
Posts (Atom)